Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19003642 | 0.93 | ESR1 (0.37) | S1PR1ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL12735675 | 0.89 | S1PR1 (0.41) | S1PR1KEAP1 | |
| SCHEMBL20459002 | 0.86 | CYP3A4 (0.38) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21164523 | 0.81 | SLC6A4 (0.36) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20090990 | 0.80 | KMT2A (0.39) | S1PR1SLC6A2SLC6A4SLC6A3KEAP1 | |
| SCHEMBL19003641 | 0.79 | L3MBTL1 (0.42) | — | |
| SCHEMBL20646210 | 0.79 | SKP2 (0.43) | ESR1ESR2SLC6A2SLC6A3 | |
| SCHEMBL21466596 | 0.79 | ESR1 (0.35) | ESR1ESR2 | |
| SCHEMBL13093046 | 0.79 | ESR1 (0.44) | ESR1ESR2 | |
| SCHEMBL27472082 | 0.77 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | S1PR1 166/4885ESR1 3323/4885ESR2 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.